Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

DBV Technologies

DBVT
Current price
7.98 USD +0.07 USD (+0.88%)
Last closed 7.44 USD
ISIN US23306J1016
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 218 144 480 USD
Yield for 12 month +20.73 %
1Y
3Y
5Y
10Y
15Y
DBVT
21.11.2021 - 28.11.2021

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. The company's product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France. Address: Bâtiment IRO, Châtillon, France, 92320

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

23.68 USD

P/E ratio

Dividend Yield

Current Year

Last Year

+15 728 000 USD

Current Quarter

Last Quarter

Current Year

Last Year

+15 728 000 USD

Current Quarter

Last Quarter

Key Figures DBVT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -79 693 000 USD
Operating Margin TTM -4 669.47 %
Price to Earnings
Return On Assets TTM -58.61 %
PEG Ratio
Return On Equity TTM -135.96 %
Wall Street Target Price 23.68 USD
Revenue TTM 4 151 000 USD
Book Value 0.27 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -94.20 %
Dividend Yield
Gross Profit TTM 4 151 000 USD
Earnings per share -5.85 USD
Diluted Eps TTM -5.85 USD
Most Recent Quarter IV 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics DBVT

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History DBVT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor 1:2
Payout Ratio
Last Split Date 07.06.2024

Stock Valuation DBVT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM 52.55
Enterprise Value EBITDA -2.07
Price Book MRQ 7.97

Financials DBVT

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators DBVT

For 52 weeks

2.20 USD 8.50 USD
50 Day MA 5.25 USD
Shares Short Prior Month 340 543
200 Day MA 2.60 USD
Short Ratio 0.54
Shares Short 561 856
Short Percent 0.33 %